Rapid7, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Rapid7, Inc. (NASDAQ: RPD) provides cybersecurity software and services focused on vulnerability management, threat detection and response, exposure management, and security operations automation through its unified Command platform. The company offers core products and services including InsightVM for vulnerability management; InsightIDR for next-generation SIEM, detection and response with user behavior analytics, endpoint detection, and network analysis; InsightAppSec for application security; exposure management for continuous attack surface assessment; attack surface management with cyber asset inventory; cloud security solutions for multi-cloud visibility and risk monitoring; threat intelligence for external threat remediation; Metasploit for open-source penetration testing; and managed detection and response (MDR) services with 24/7 incident response. Additional offerings encompass professional services such as penetration testing, incident response, security advisory, IoT testing, threat modeling, deployment, and training, delivered via cloud subscriptions, managed services, and on-premises licenses. Rapid7 serves enterprises and mid-market organizations across industries including energy, financial services, government, education, retail, and healthcare, with primary operations in North America and presence worldwide. Founded in 2000 and headquartered in Boston, Massachusetts, the company operates from its principal address at 120 Causeway Street, Suite 400. Rapid7 targets security teams seeking to prioritize risks, automate remediation, and integrate visibility across hybrid, cloud, and endpoint environments. In recent developments, Rapid7 agreed to acquire Noetic Cyber in July 2024, a cyber asset attack surface management (CAASM) provider, to enhance asset inventory visibility for internal and external environments, with capabilities made available to customers in summer 2024 and closure expected in fiscal Q3 2024. The company also announced its 2025 Partner of the Year Awards in March 2025, recognizing global partners for excellence in cybersecurity delivery and customer retention. In March 2025, Rapid7 added three new directors to its board, including a partner from activist investor Jana Partners, as part of a settlement to strengthen governance. These moves support ongoing platform consolidation and growth, with annualized recurring revenue reaching $838 million as of Q3 2025.
Company News
Rapid7 to Participate in Upcoming Investor Conferences
Rapid7 Inc (RPD) Shares Fall 7.8% -- What GF Score of 54 Tells Investors
Rapid7: Q2 Beat Validates The Bull Case
Rapid7 Finds Nearly Two-Thirds of Vulnerabilities Exploited in Q2 2026 Required No User Interaction to Initiate
Is Rapid7 (RPD) a Great Value Stock Right Now?
Rapid7 Inc (RPD) Shares Fall 8.2% -- What GF Score of 59 Tells Investors
Rapid7-Omdia Research Reveals AI Governance Gap as Executive Security Leaders Show 1.6x Greater Concern Than Practitioners
Rapid7 Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Earnings
Rapid7 Q2 Earnings Call Highlights
Rapid7 (RPD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Rapid7, Inc. (RPD) Q2 2026 Earnings Call Transcript
Rapid7 (RPD) Q2 Earnings and Revenues Top Estimates
Stay Ahead of the Game With Rapid7 (RPD) Q2 Earnings: Wall Street's Insights on Key Metrics
Rapid7 Becomes First Major Security Operations Platform to Unite SecOps and GRC
5 Takeover Targets for the AI Revolution
Rapid7 to Report Second Quarter 2026 Financial Results on August 10
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
Rapid7 (RPD) Moves 7.6% Higher: Will This Strength Last?
Reveal Expands European Offerings with Private Deployment, AI-Powered Review and Logikcull's Government Transparency Solutions